Arena Pharmaceutical (ARNA), a company operating in the healthcare sector, is involved in developing and commercializing drugs that target 'G-protein coupled receptors'. A key highlight for the quarter was Arena acquiring an approval for its weight loss drug, Lorcaserin, marketed under the trade name Belviq. After the company reported its financial results on Thursday, its stock fell by approximately 1.2% to $7.27, from $7.36.
Read more: http://seekingalpha.com/article/803171-buy-arena-before-european-approval-comes-through
Read more: http://seekingalpha.com/article/803171-buy-arena-before-european-approval-comes-through
